{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:02:16Z","timestamp":1784048536611,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011517","name":"Lucille P. Markey Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011517","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.urolonc.2019.06.020","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T17:42:11Z","timestamp":1563385331000},"page":"572.e1-572.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Predictive value of phenotypic signatures of bladder cancer response to cisplatin-based neoadjuvant chemotherapy"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8098-901X","authenticated-orcid":false,"given":"Patrick J.","family":"Hensley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Kyprianou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Purdom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"DiCarlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2019.06.020_bib0001","unstructured":"American Cancer Society.http:\/\/www.cancer.org\/cancer\/bladdercancer\/detailedguide\/bladder-cancer-key-statistics. Accessed September 21, 2018."},{"key":"10.1016\/j.urolonc.2019.06.020_bib0002","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2019.06.020_bib0003","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","author":"Griffiths","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2019.06.020_bib0004","doi-asserted-by":"crossref","first-page":"e851","DOI":"10.1016\/j.clgc.2018.02.007","article-title":"Optimization of patient selection for neoadjuvant chemotherapy in muscle-invasive urothelial carcinoma of the bladder","volume":"16","author":"Hensley","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2019.06.020_bib0005","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.urology.2016.10.064","article-title":"Assessing cancer progression and stable disease after neoadjuvant chemotherapy for organ-confined muscle-invasive bladder cancer","volume":"102","author":"Chappidi","year":"2017","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.urolonc.2019.06.020_bib0006","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2018.07.036","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"174","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"7492","key":"10.1016\/j.urolonc.2019.06.020_bib0007","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.urolonc.2019.06.020_bib0008","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sj\u00f6dahl","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.urolonc.2019.06.020_bib0009","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/jnci\/djx243","article-title":"Prognostic power of a tumor differentiation gene signature for bladder urothelial carcinomas","volume":"110","author":"Mo","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.urolonc.2019.06.020_bib0010","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1073\/pnas.1120605109","article-title":"Three differentiation states risk-stratify bladder cancer into distinct subtypes","volume":"109","author":"Volkmer","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.urolonc.2019.06.020_bib0011","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.eururo.2015.08.034","volume":"69","author":"McConkey","year":"2016","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2019.06.020_bib0012","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.urolonc.2019.06.020_bib0013","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2019.06.020_bib0014","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.humpath.2016.06.020","article-title":"Association of epithelial-mesenchymal transition and nuclear cofilin with advanced urothelial cancer","volume":"57","author":"Hensley","year":"2016","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.urolonc.2019.06.020_bib0015","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2019.06.020_bib0016","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.eururo.2017.05.016","article-title":"Oncologic outcomes for patients with residual cancer at cystectomy following neoadjuvant chemotherapy: a pathologic stage-matched analysis","volume":"72","author":"Bhindi","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2019.06.020_bib0017","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.clgc.2015.09.013","article-title":"Predictors of complete pathologic response (pT0) to neoadjuvant chemotherapy in muscle-invasive bladder carcinoma","volume":"14","author":"Pokuri","year":"2016","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2019.06.020_bib0018","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1464-410X.2012.11370.x","article-title":"Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy","volume":"111","author":"Green","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2019.06.020_bib0019","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.juro.2010.01.028","article-title":"Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer","volume":"183","author":"Stimson","year":"2010","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2019.06.020_bib0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/pros.23708","article-title":"TGF-\u03b2 receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer","volume":"79","author":"Paller","year":"2018","journal-title":"Prostate"},{"issue":"45","key":"10.1016\/j.urolonc.2019.06.020_bib0021","doi-asserted-by":"crossref","first-page":"78507","DOI":"10.18632\/oncotarget.19659","article-title":"Reversion of epithelial-mesenchymal transition by a novel agent DZ-50 via IGF binding protein-3 in prostate cancer cells","volume":"8","author":"Cao","year":"2017","journal-title":"Oncotarget"},{"issue":"16","key":"10.1016\/j.urolonc.2019.06.020_bib0022","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/pros.23435","article-title":"Predictive value of epithelial-mesenchymal-transition (EMT) signature and PARP-1 in prostate cancer radioresistance","volume":"77","author":"Stark","year":"2017","journal-title":"Prostate"},{"issue":"11","key":"10.1016\/j.urolonc.2019.06.020_bib0023","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1093\/carcin\/bgu183","article-title":"PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis","volume":"35","author":"Pu","year":"2014","journal-title":"Carcinogenesis"},{"issue":"3","key":"10.1016\/j.urolonc.2019.06.020_bib0024","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bbamcr.2018.10.003","article-title":"Cofilin-1 signaling mediates epithelial-mesenchymal transition by promoting actin cytoskeleton reorganization and cell-cell adhesion regulation in colorectal cancer cells","volume":"1866","author":"Sousa-Squiavinato","year":"2018","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"10.1016\/j.urolonc.2019.06.020_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2017.01.002","article-title":"Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer","volume":"54","author":"Buttigliero","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urolonc.2019.06.020_bib0026","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1046\/j.1464-410x.2000.00895-6.x","article-title":"Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy","volume":"86","author":"Duggan","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2019.06.020_bib0027","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/jnci\/djx254","article-title":"Subtyping bladder cancers: biology vs bioinformatics","volume":"110","author":"McConkey","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2019.06.020_bib0028","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","article-title":"Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use","volume":"12","author":"Dadhania","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.urolonc.2019.06.020_bib0029","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.ajpath.2013.05.013","article-title":"Toward a molecular pathologic classification of urothelial carcinoma","volume":"183","author":"Sj\u00f6dahl","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.urolonc.2019.06.020_bib0030","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","article-title":"Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer","volume":"61","author":"Rosenblatt","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2019.06.020_bib0031","doi-asserted-by":"crossref","first-page":"11702","DOI":"10.1038\/s41598-017-11291-0","article-title":"Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer","volume":"15","author":"Thomsen","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2019.06.020_bib0032","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.urolonc.2016.03.004","article-title":"Taking the next step-advancing bladder cancer management","volume":"34","author":"Vlahou","year":"2016","journal-title":"Urol Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143919302492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143919302492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:14:47Z","timestamp":1761041687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143919302492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1078143919302492"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2019.06.020","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive value of phenotypic signatures of bladder cancer response to cisplatin-based neoadjuvant chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2019.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}